S. 4152

A bill to amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.

Latest

II

117th CONGRESS

2d Session

S. 4152

IN THE SENATE OF THE UNITED STATES

May 5, 2022

Mr. Kelly (for himself, Ms. Collins, and Ms. Sinema) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

A BILL

To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.

1.

Reauthorization of the Critical Path Public-Private Partnerships

Section 566(f) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–5(f)) is amended by striking $6,000,000 for each of fiscal years 2018 through 2022 and inserting $10,000,000 for each of fiscal years 2023 through 2027.